WP
KALV

Woodline Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Woodline Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.4M Sell
1,509,920
-411,172
-21% -$6.63M 0.11% 243
2025
Q4 		$31M Buy
1,921,092
+428
+0% +$5.67K 0.12% 222
2025
Q3 		$23.4M Hold
1,920,664
– – 0.11% 250
2025
Q2 		$21.7M Buy
1,920,664
+303,195
+19% +$3.71M 0.11% 266
2025
Q1 		$18.7M Buy
1,617,469
+329,068
+26% +$3.36M 0.12% 241
2024
Q4 		$10.9M Buy
1,288,401
+680,148
+112% +$7.04M 0.07% 322
2024
Q3 		$7.04M Buy
608,253
+457,791
+304% +$5.76M 0.06% 346
2024
Q2 		$1.77M Hold
150,462
– – 0.02% 431
2024
Q1 		$1.78M Sell
150,462
-196,401
-57% -$2.62M 0.02% 431
2023
Q4 		$4.25M Buy
+346,863
New +$3.16M 0.05% 332
2023
Q3 		– Sell
-108,358
Closed -$975K – 674
2023
Q2 		$975K Buy
+108,358
New +$999K 0.01% 486
2023
Q1 		– Sell
-593,810
Closed -$4.01M – 708
2022
Q4 		$4.01M Sell
593,810
-159,071
-21% -$852K 0.05% 351
2022
Q3 		$10.9M Sell
752,881
-334,002
-31% -$4.67M 0.15% 190
2022
Q2 		$10.7M Buy
1,086,883
+589,869
+119% +$6.51M 0.16% 166
2022
Q1 		$7.33M Buy
497,014
+358,276
+258% +$5.15M 0.12% 207
2021
Q4 		$1.84M Buy
138,738
+9,387
+7% +$149K 0.03% 435
2021
Q3 		$2.26M Buy
129,351
+27,645
+27% +$560K 0.04% 395
2021
Q2 		$2.44M Sell
101,706
-122,353
-55% -$3.2M 0.05% 327
2021
Q1 		$5.76M Buy
+224,059
New +$5.89M 0.13% 179

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners's KALV Position: Q1 2026 in Review

Woodline Partners reduced its KalVista Pharmaceuticals (KALV) stake by 21% in Q1 2026, selling an estimated $6.63M and leaving 1,509,920 shares worth $30.4M. The position accounts for 0.11% of the portfolio, ranked #243.

Woodline Partners first reported a position in KALV in Q1 2021 and has held it in 19 quarters since. The position peaked at $31M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Woodline Partners held 1,509,920 shares of KalVista Pharmaceuticals worth $30.4M as of Q1 2026.
  • Woodline Partners sold 411,172 KalVista Pharmaceuticals shares in Q1 2026, an estimated $6.63M.
  • KalVista Pharmaceuticals made up 0.11% of Woodline Partners's portfolio in Q1 2026, its #243 holding.
  • Woodline Partners first reported a position in KalVista Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
  • Woodline Partners's KalVista Pharmaceuticals position peaked at $31M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.